000 04090cam a2200721 i 4500
001 sulb-eb0033980
003 BD-SySUS
005 20170713221424.0
006 m o d
007 cr |||||||||||
008 150803s2015 nju o 001 0 eng
010 _a 2015030480
040 _aDLC
_beng
_erda
_cDLC
_dOCLCF
_dN$T
_dDG1
_dYDXCP
_dCOO
_dIDEBK
_dCDX
_dEBLCP
_dRECBK
_dDEBBG
_dKSU
_dDEBSZ
_dBD-SySUS
020 _a9781118914342 (epub)
020 _a1118914341 (epub)
020 _a9781118819449 (pdf)
020 _a1118819446 (pdf)
020 _z9781118679678 (cloth)
020 _a9781118819586
020 _a1118819586
020 _a1118679679 (cloth)
020 _a9781118679678 (cloth)
029 1 _aDEBBG
_bBV043399087
029 1 _aDEBSZ
_b480371997
035 _a(OCoLC)915775232
042 _apcc
050 0 0 _aHD9665.5
072 7 _aMED
_x071000
_2bisacsh
082 0 0 _a615.1068/5
_223
049 _aMAIN
100 1 _aAlex, Alexander A.,
_eeditor.
245 1 0 _aAttrition in the pharmaceutical industry :
_breasons, implications, and pathways forward /
_cedited by Alexander A. Alex, C. John Harris, Dennis A. Smith.
264 1 _aHoboken, New Jersey :
_bJohn Wiley & Sons,
_c2015.
300 _a1 online resource.
336 _atext
_2rdacontent
337 _acomputer
_2rdamedia
338 _aonline resource
_2rdacarrier
500 _aIncludes index.
505 0 _aAttrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis -- Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop -- Attrition in phase I / Dennis A. Smith and Thomas A. Baillie -- Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith -- Post-marketing attrition / Dennis A. Smith -- Influence of the regulatory environment on attrition / Robert T. Clay -- Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt -- Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy -- Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams -- In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis -- Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale -- Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton.
588 _aDescription based on print version record and CIP data provided by publisher.
650 0 _aPharmaceutical industry
_xManagement.
650 0 _aPharmaceutical industry
_xCapital productivity.
650 0 _aIndustrial efficiency.
650 0 _aDrug development.
650 7 _aDrug development.
_2fast
_0(OCoLC)fst00898670
650 7 _aIndustrial efficiency.
_2fast
_0(OCoLC)fst00970970
650 7 _aPharmaceutical industry
_xCapital productivity.
_2fast
_0(OCoLC)fst01767658
650 7 _aPharmaceutical industry
_xManagement.
_2fast
_0(OCoLC)fst01060159
650 7 _aMEDICAL / Pharmacology
_2bisacsh
655 4 _aElectronic books.
700 1 _aHarris, C. John,
_eeditor.
700 1 _aSmith, Dennis A.,
_eeditor.
776 0 8 _iPrint version:
_aAlex, Alexander A., editor.
_tAttrition in the pharmaceutical industry
_dHoboken, New Jersey : John Wiley & Sons, 2015
_z9781118679678
_w(DLC) 2015024772
856 4 0 _uhttp://onlinelibrary.wiley.com/book/10.1002/9781118819586
_zWiley Online Library [Free Download only for SUST IP]
938 _aEBSCOhost
_bEBSC
_n1087869
938 _aYBP Library Services
_bYANK
_n12675631
938 _aYBP Library Services
_bYANK
_n12697515
938 _aIngram Digital eBook Collection
_bIDEB
_ncis31645667
938 _aCoutts Information Services
_bCOUT
_n31645667
938 _aEBL - Ebook Library
_bEBLB
_nEBL4435614
938 _aRecorded Books, LLC
_bRECE
_nrbeEB00659297
994 _a92
_bDG1
999 _c65632
_d65632